Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Contract Assets and Liabilities

The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):

	March 31, 2023		December 31, 2022
Current pharma contract assets (1)	$	1,121	$	1,898
Long-term pharma contract assets (2)	—		31
Total pharma contract assets	$	1,121	$	1,929
Current pharma capitalized commissions (1)	$	912	$	800
Long-term pharma capitalized commissions (2)	632		715
Total pharma capitalized commissions	$	1,544	$	1,515
Current pharma contract liabilities	$	6,067	$	7,557
Long-term pharma contract liabilities (3)	—		19
Total pharma contract liabilities	$	6,067	$	7,576

(1) Recorded within other current assets on the Consolidated Balance Sheets.

(2) Recorded within other assets on the Consolidated Balance Sheets.

(3) Recorded within other long-term liabilities on the Consolidated Balance Sheets.

Schedule of Disaggregation of Revenue

The following table details the disaggregation of revenue for both the Clinical Services and Pharma Services segments (in thousands):

	Three Months Ended March 31,
	2023		2022
Clinical Services:
Client direct billing	$	76,823	$	65,014
Commercial Insurance	21,355		18,288
Medicare and Medicaid	16,587		15,465
Self-Pay	104		24
Total Clinical Services	$	114,869	$	98,791
Pharma Services	22,351		18,378
Total Revenue	$	137,220	$	117,169